期刊文献+

非酒精性脂肪性肝病大鼠肝脏脂联素受体的表达 被引量:1

Expression of adiponectin receptor of liver in rats with nonalcoholic fatty liver disease
下载PDF
导出
摘要 目的探讨非酒精性脂肪性肝病(NAFLD)大鼠肝脏脂联素受体(AdipoR)mRNA的表达。方法喂养高脂饲料建立NAFLD大鼠模型,分别于2、4、8、12周检测血清生化指标,并取肝组织测肝指数(肝湿重/体重),以RT-PCR法检测肝脏AdipoR1和AdipoR2 mRNA的表达,肝组织冰冻切片苏丹Ⅲ脂肪染色、石蜡切片苏木素-伊红常规染色和Masson三色纤维染色,镜下观察。结果模型组大鼠2、4、8、12周肝脏AdipoR1 mRNA表达逐步上升,AdipoR2 mRNA表达逐步下降,两者分别于4周、2周开始显著差异于对照组(P均<0.01)。模型组肝脏AdipoR2表达与肝指数(r=-0.431,P=0.006)、纤维化评分(r=-0.353,P=0.025)均呈显著负相关。结论NAFLD大鼠肝脏AdipoR1 mRNA表达增加,AdipoR2 mRNA表达减少,提示肝脏AdipoR表达异常可能参与NAFLD的发病机制。 Objective To investigate the expression of hepatic adiponectin receptor in the rats with nonalcoholic fatty liver diseases(NAFLD). Methods The NAFLD model rats were induced by high fat diet. The rats were killed at 2, 4, 8, 12 weeks respectively. The serum biochemical parameters were measured, liver index evaluated and hepatic AdipoR1 mRNA and AdipoR2 mRNA expressions measured by RT-PCR. Liver slices were analyzed for pathological changes. Results In the model group, the expression of hepatic AdipoR1 mRNA were gradually increased, the AdipoR2 mRNA expression decreased as compared with the control group (P 〈 0. 01 ). AdipoR2 expression was negatively correlated with liver index ( r = -0. 431, P = 0. 006) and hepatic fibrosis scale ( r = - 0. 353, P =0. 025 ) with statistical significance, respectively. Conclusion Hepatic AdipoR1 mRNA expression were increased and the AdipoR2 mRNA expression decreased in NAFLD rats. The results indicate that abnormal hepatic AdipoR expression may be related to the pathogenesis of NAFLD.
出处 《胃肠病学和肝病学杂志》 CAS 2008年第10期802-805,共4页 Chinese Journal of Gastroenterology and Hepatology
基金 上海市自然科学基金项目(05ZR14156)
关键词 脂肪肝 非酒精性 脂联素受体 Fatty liver Non-alcoholic Adiponectin receptor
  • 相关文献

参考文献10

  • 1Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease [J]. Diabetes Obes Metab, 2007, 9(3): 282-289.
  • 2钟岚,范建高,王国良,吴伟清,史祺.肥胖、高脂血症性脂肪性肝炎模型的建立[J].实验动物科学与管理,2000,17(2):16-20. 被引量:139
  • 3Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1512
  • 4Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease [ J ]. Eur J Endocrinol, 2005, 152(1): 113-118.
  • 5Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte derived plasma protein, inhibites endothelial NF-kappa B signaling through a cAMPK dependent pathway [ J ]. Circulation, 2000, 102 ( 11 ) : 1296- 1301.
  • 6Neumeier M, Weigert J, Schaffler A, et al. Regulation of adiponcctin receptor 1 in human hepatocytes by agonists of nuclear receptors [ J]. Biochem Biophys Res Commun, 2005, 334(3) :924-929.
  • 7Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in nonalcoholic steatohepatitis [ J]. Gut, 2005, 54( 1 ) : 117-121.
  • 8Shimizu A, Takamura T, Matsuzawa N, et al. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line [ J]. Metabolism, 2007, 56(11): 1478-1485.
  • 9Bjursell M, Ahnmark A, Bohlooly-Y M, et al. Opposing effects of adiponectin receptors l and 2 on energy metabolism [ J ]. Diabetes, 2007, 56(3) : 583-593.
  • 10Barnea M, Shamay A, Stark AH, et al. A high-fat diet has a tissuespecific effect on adip.onectin and related enzyme expression [ J]. Obesity (Silver Spring), 2006, 14(12): 2145-2153.

二级参考文献19

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 3Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 4Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.
  • 5Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
  • 6Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
  • 7Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
  • 8Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261.
  • 9Comar KM,Sterling RK.Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacal Ther,2006,23:207-215.
  • 10Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.

共引文献1643

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部